ERBITUX® (Cetuximab) Receives Approval In Japan For Use In Advanced Colorectal Cancer

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that ERBITUX® (cetuximab) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC).

More: continued here

Filed under: Colorectal Cancer on July 26th, 2008